Clostridioides Difficile InfectionPhase 3Ri-CoDIFy 1NCT03595553
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
A Phase 3 study testing Ridinilazole and Vancomycin in people with Clostridioides Difficile Infection, run by Summit Therapeutics at 149 sites in 14 countries.
Trial summary
Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of demonstrating an improved Sustained Clinical Response rate in subjects treated with ridinilazole as compared to subjects treated with vancomycin. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Clostridioides Difficile Infection
- What is being tested?
- Ridinilazole and Vancomycin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 759 participants
- Where
- 149 sitesin 14 countries
- Study dates
- 28 Jan 2019to 17 Nov 2021
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients are eligible to be included in the study only if all the following criteria apply:
- Patient must be at least 18 years of age, at the time of signing the informed consent.
- Have signs and symptoms of CDI including diarrhea such that in the Investigator's opinion, CDI antimicrobial therapy is required. Diarrhea is defined as a change in bowel habits, with ≥3 unformed bowel movements (UBMs) (5, 6 or 7 on the Bristol Stool Chart) in the 24 h prior to randomization.
- Have the presence of either toxin A and/or B of C. difficile in the stool determined by a positive free toxin test (using a Sponsor agreed test). The stool sample must be current (produced within 72 hours prior to randomization).
- Male or Female
- Male patients:
Show all 10Show fewer
- A male patient must agree to use contraception as detailed in Section 10.4 of this protocol during the treatment period and for at least 30 days after the last dose of study treatment and refrain from donating sperm during this period.
- Female patients:
- A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: i. Not a woman of childbearing potential (WOCBP) OR ii. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 30 days after the last dose of study treatment.
- Has provided documented signed informed consent and any authorizations required by local law (e.g. Protected Health Information [PHI]). If unable to read, understand and sign the informed consent form a legally authorized representative (LAR) may provide consent on the patient's behalf if permitted by the Institutional Review Board (IRB)/Ethics Committee (EC).
Who cannot join
- Patients are excluded from the study if any of the following criteria apply:
- Have had more than one prior episode of CDI in the previous 3 months or more than 3 episodes in the past 12 months prior to randomization.
- Have a history of chronic diarrheal disease including inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- Have had a positive diagnostic test for other GI pathogens, considered to be clinically relevant, within 2 weeks of randomization.
- Have had major gastrointestinal (GI) surgery (e.g. significant bowel resection) within 3 months of randomization (this does not include appendectomy). The presence of a colostomy or ileostomy or likely requirement of an ostomy during the study.
- Have life threatening or fulminant CDI with evidence of hypotension, septic shock, peritoneal signs or absence of bowel sounds, or toxic megacolon.
Show all 17Show fewer
- History of bone marrow or hematopoietic stem cell transplant at any time or a known current history of a severely compromised/suppressed immune system that, in the opinion of the Investigator, would make the patient unsuitable for the study.
- Have had more than the equivalent of 24 hours of dosing of antimicrobial treatment active against the current episode of CDI prior to randomization. (i.e. more than four doses of oral vancomycin, two doses of fidaxomicin or three doses of metronidazole).
- Prior or current use of anti-toxin antibodies including bezlotoxumab within the past 6 months prior to randomization.
- Are unable to discontinue products used affecting disease progression at randomization.
- Has been involved in a clinical trial and received an investigational medicinal product for indications other than CDI within 1 month or five half-lives (whichever is longer) or within 3 months if the investigational medical product was for CDI.
- Have received an investigational vaccine against C. difficile.
- Patients that the Investigator feels are inappropriate for the study this would include those;
- with any other condition that, in the Investigator's judgment, would make the patient unsuitable for inclusion in the study.
- who, in the opinion of the Investigator, are not likely to complete the study for whatever reason, e.g. short life expectancy.
- with known hypersensitivity or intolerance to ridinilazole, vancomycin, and/or their excipients
- who are unwilling or unable to comply with protocol requirements, e.g. complete the full course of study treatment per schedule, attend study visits, report diarrhea/suspected recurrence, provide stool samples, ingest capsules/tablets or blood draws.
Trial locations and contacts
149 sites in 14 countries.
149 sites in 14 countries
United States49 sites
GI Alliance - Texas Digestive Disease Consultants - Arlington
Arlington, Texas, 76012
University of Maryland School of Medicine
Baltimore, Maryland, 21201
University of Alabama - Birmingham
Birmingham, Alabama, 35233
Mercury Street Medical Group PLLC
Butte, Montana, 59701
GI Alliance - Texas Digestive Disease Consultants - Cedar Park
Cedar Park, Texas, 78613
Chattanooga Research and Medicine CHARM
Chattanooga, Tennessee, 37404-3230
DM Clinical Research (Conroe Regional Hospital)
Conroe, Texas, 77304
Infectious Disease Specialists of Atlanta
Decatur, Georgia, 30333
Harper Hospital Department of Pharmacy Services
Detroit, Michigan, 48201-2020
Detroit Receiving Hospital Department of Pharmacy Services
Detroit, Michigan, 48201
Aa Mrc Llc
Flint, Michigan, 48504-4730
Midway Immunology and Research Center
Ft. Pierce, Florida, 34982
GI Alliance - Illinois Gastro Group - Glenview
Glenview, Illinois, 60026
ECU Adult Specialty Care
Greenville, North Carolina, 27834
Grand Teton Research Group PLLC
Idaho Falls, Idaho, 83404
The University of Kansas Medical Center
Kansas City, Kansas, 66160
FMC Science
Lampasas, Texas, 76550
AB Clinical Trials
Las Vegas, Nevada, 89119
Alliance Medical Research LLC
Lighthouse PT, Florida, 33064
David Geffen School of Medicine at UCLA
Los Angeles, California, 90095
Infectious Diseases Associates of Central VA
Lynchburg, Virginia, 24501
Loyola University Medical Center
Maywood, Illinois, 60153
Phoenix Medical Research LLC
Miami, Florida, 33165
San Marcus Research
Miami Lakes, Florida, 33014
Facey Medical Foundation
Mission Hills, California, 91345
Gasteroenterology Group of Naples
Naples, Florida, 31402
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
New York Presbyterian Hospital Weill Cornell
New York, New York, 10021
HeuerMD Research Inc
Orlando, Florida, 32819
Pines Care Research Center Inc.
Pembroke Pines, Florida, 33026
UnityPoint Health Peoria/Proctor
Peoria, Illinois, 61603
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213
Monument Health Clinical Research
Rapid City, South Dakota, 57701
Paradigm Clinical Research Centers, Inc
Redding, California, 96601
William Beaumont Hospital
Royal Oak, Michigan, 48073-6712
University Of California Davis
Sacramento, California, 95817
GI Alliance - Texas Digestive Disease Consultants - San Marcos
San Marcos, Texas, 78666
Bardmoor Gastroenterology
Seminole, Florida, 33777
Revival Research Institute, LLC.
Southfield, Michigan, 48034
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Professional Health Care of Pinellas
St. Petersburg, Florida, 33713
GI Alliance - Arizona Digestive Health - Sun City
Sun City, Arizona, 85351
James J. Peters VAMC
The Bronx, New York, 10468
St. Vincent Mercy Medical Center
Toledo, Ohio, 43608
Carle Foundation Hospital
Urbana, Illinois, 61801
GI Alliance - Texas Digestive Disease Consultants - Webster
Webster, Texas, 77598
PMG Research of Winston-Salem
Winston-Salem, North Carolina, 27103
St. Vincent Hospital
Worcester, Massachusetts, 01608-1216
Florida Medical Clinic P.A.
Zephyrhills, Florida, 33542
South Korea15 sites
Hanyang University Seoul Hospital
Ansan, Seoul, 04763
Korea University Ansan Hospital
Ansan-si, Gyeonggi-do, 15355
Hallym University Kangnam Sacred Heart Hospital
Anyang-si, Seoul, 07441
Hallym University Chuncheon Sacred Heart Hospital
Chuncheon, Gangwon-do, 24253
Kyungpook National University Hospital
Daegu, Seoul, 41944
Yeungnam University Medical Center
Daegu, Seoul, 42415
Keimyung University Dongsan Hospital
Daegu, Yeongnam, 42601
Hanyang University Guri Hospital
Guri-si, Gyeonggi-do, 11923
Wonju Severance Christian Hospital
Ilsan-dong, Gangwondo, 26426
Samsung Medical Center
Irwon-dong, Seoul, 06351
Inje University Seoul Paik Hospital
Junggu, 04551
Kangbuk Samsung Hospital
Seoul, 03181
Kangdong Sacred Heart Hospital
Seoul, 05355
Korea University Guro Hospital
Soeul, 08307
Asan Medical Center
Soeul, 5505
Poland12 sites
SP ZOZ w Bochni Szpital Powiatowy im. B. Marty Wieckiej
Bochnia, 32-700
Szpital Bocheński SP ZOZ w Bochni
Bochnia, 32-700
Klinika Chorób Zakaźnych i Hepatologii Wojewódzki Szpital Obserwacyjno-Zakaźny im. Tadeusza Browicza
Bydgoszcz, 85-030
Szpital Specjalistyczny w Chorzowie
Chorzów, 41-500
Szpital Zakonu Bonifratrów
Katowice, 40-211
Specjalistyczne Gabinety Sp z o.o.
Krakow, 30-539
Gabinet Lekarski Bartosz Korczowski
Rzeszów, Podkarpackie Voivodeship, 35-302
Korczowski Bartosz Gabinet
Rzeszów, 35-302
ENDOSKOPIA Sp. z o.o.
Sopot, 81-756
Centralny Szpital Kliniczny MSWiA Klinika Chorób Wewnętrznych i Gastroenterologii
Warsaw, 02-507
Klinika Chorób Wewnętrznych i Gastroenterologii z Pododdziałem Leczenia Nieswoistych Chorób Zapalnych Jelit Centralny Szpital Kliniczny MSWiA
Warsaw, 02-507
Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego we Wrocławiu; I Oddział Chorób Zakaźnych
Wroclaw, 51-149
Hungary11 sites
Dr. Kenessey Albert Kórház Rendelőintézet, Tüdőgyógyászati Aktív Osztály
Balassagyarmat, 2660
Békés Megyei Központi Kórház Dr. Réthy Pál Tagkórház IV. Belgyógyászat - 2. Gasztroenterológia
Békéscsaba, 5600
"Dél-Pesti Centrumkórház-OHII Szent László Kórház Infektológiai Osztály "
Budapest, H-1097
Országos Korányi Pulmonológiai Intézet, Központi Intenzív osztály
Budapest, H-1122
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház, Infektológia-Hepatológia Osztály
Gyula, Bekes County, 5700
Pest Megyei Flór Ferenc Kórház, V. Belgyógyászat
Kistarcsa, Pest County, 2143
CRU Hungary Kft BAZ Megyei Kórház és Egyetemi Oktatókórház, Szent Ferenc Tagkórház
Miskolc, 3529
"Pécsi Tudományegyetem I. sz. Belgyógyászat i Klinika, Infektológiai tanszék"
Pécs, H-7623
Pécsi Tudományegyetem Klinikai Központi Gyógyszertár
Pécs, H-7624
Csongrad County Dr. Bugyi Istvan Hospital, Dept. Of Internal Medicine
Szentes, H-6600
Javorszy Odon Hospital
Vác, Vác, 2600
Romania9 sites
SUUMC-Boli infectioase
Bucharest, 010825
Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes"
Bucharest, 030303
S.C. Sana Monitoring Srl
Bucharest, 11025
Spitalul Clinic de Boli Infectioase si Tropicale
Bucharest, 30303
Spitalul Minicipal Caracal
Caracal, 235200
Spitalul Clinic de Boli Infectioase Constanta
Constanța, 900709
Spitalul Clinic de Boli Infectioase- Sfanta Parascheva
Iași, 700722
Spitalul Clinic de Boli Infectioase
Iași, 700722
Spitalul Clinic Judetean de Urgenta Timisoara
Timișoara, 300723
Brazil8 sites
Unidade de Pesquisa - NCS - Hospital Felício Rocho
Belo Horizonte, Minas Gerais, 30110-936
Hospital Vera Cruz
Belo Horizonte, Minas Gerais, 30140-030
Santa Casa De Misericordia De Belo Horizonte
Belo Horizonte, Minas Gerais, 30150221
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90020090
Hospital das Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90035-903
Hospital Ernesto Dornelles
Porto Alegre, Rio Grande do Sul, 90160-092
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, 15090-000
Hospital Alemao Oswaldo Cruz
São Paulo, São Paulo, 01327-001
Greece8 sites
General Hospital of Athens ''Evangelismos'
Athens, 10676
General Hospital of Athens ''Alexandra''
Athens, 115-28
"Pathophysiology Department Athens University Medical School"
Athens, 11527
" ATTIKON University Hospital"
Athens, 12462
"'Hygeia'' Hospital 2nd Department of Medicine and Infectious Diseases"
Athens, 15121 Marousi
University Hospital of Heraklion
Heraklion, 71110
University Hospital of Patras
Pátrai, 265 04
''Tzaneio'' General Hospital of Piraeus
Piraeus, 185 -36
Spain8 sites
Hospital Universitario Cruces
Barakaldo, 48903
Hospital de la Santa Creu i Sant Pau
Barcelona, 8041
Hospital Universitario Reina Sofía. Hospital Provincial
Córdoba, 14004
"Hospital Universtiario Donostia "
Donostia / San Sebastian, 20014
Hospital General Universitario Gregorio Marañon
Madrid, 28007
"Hospital Universitario Marqués de Valdecilla "
Santander, 39008
Hospital Universitario de Balme
Seville, Sevilla, 41014
Hospital Universitari Sant Joan de Reus
Tarragona, 43204
Canada7 sites
Foothills Medical Centre, South Tower
Calgary, Alberta, T2N 2T9
Moncton Hospital/Horizon Health Network
Moncton, New Brunswick, E1C 6Z8
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 1R9
Lakeridge Health
Oshawa, Ontario, L1G 2B9
Institut Universitaire de Cardiologie et de Pneumologie de Québec- ULaval
Québec, Quebec, G1V 4G5
Recherche Médicale St-Jérôme Inc
Québec, Quebec, J7Z 5T3
Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec
Trois-Rivières, Quebec, G8Z 3R9
Argentina6 sites
Instituto Medico Platense
Buenos Aires, BI900AVG
Hospital Italiano de Buenos Aires
Buenos Aires, C1199ABB
Hospital Ramos Mejía
Buenos Aires, C1221ADC
Hospital Privado Centro Medico Cordoba
Córdoba, X5016KEH
Centro Médico Talar
El Talar, Buenos Aires, 1608
Instituto Medico ALAS
Salta, Argentina, CP4400
Australia6 sites
Sunshine Coast University Hospital
Birtinya, Queensland, 4575
Monash Medical Center
Clayton, Victoria, 3168
Fiona Stanley Hospital
Murdoch, Western Australia, 6150
Mater Misericordiae
South Brisbane, Queensland, 4101
Westmead Hospital
Westmead, New South Wales, 2145
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102
Bulgaria5 sites
"MHAT - Blagoevgrad, EOOD Department of Gastroenterology"
Blagoevgrad, 2700
MHAT "Sv.Ivan Rilski-2003"OOD
Dupnitsa, Kyustendil, 2600
DCC1-Sliven Ltd.
Sliven, Sliven, 8800
DCC Alexandrovska
Sofia, Sofia, 1431
Medical center - Izgrev
Sofia, 1612
New Zealand3 sites
Waikato District Health Board Waikato Hospital
Hamilton, Waikato Region, 3240
Taranaki District Health Board TDHB - Taranaki Base Hospital
New Plymouth, Taranki, 4310
Waitemata District Health Board WDHB North Shore Hospital
Takapuna, Auckland, 0740
Russia2 sites
" State Budgetary Institution of Healthcare "City Clinical Hospital of n.a. V.M.Buyanova" "
Moscow, 115516
State budget healthcare institution of Novosibirsk region "City clinical hospital #2"
Novosibirsk, 630051
About this study
Official title: A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)
Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of demonstrating an improved Sustained Clinical Response rate in subjects treated with ridinilazole as compared to subjects treated with vancomycin.
A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these attributes with a comparable safety profile. A high fecal concentration of ridinilazole and little systemic exposure were noted.
Read more
The rationale for this phase 3 study is to confirm the improvement in sustained clinical response of CDI over vancomycin and to compare the safety and tolerability of ridinilazole to that of vancomycin.
Ridinilazole plasma concentration will be assessed in a subset of patients.
- Conditions
- Clostridioides Difficile Infection
- Being tested
- Ridinilazole, Vancomycin
- Keywords
- Clostridioides difficile, Clostridium difficile, C. difficile, C. diff
- Medical subject headings
- Clostridium Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RidinilazoleDrug
Also called 2,2'-di(pyridin-4-yl)-1H,1'H-5,5'-bi(benzimidazole), 2,2'-bis(4-pyridyl)-3H,3'H-5,5'-bibenzimidazole, 2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidaz
ridinilazole (200 mg bid)
VancomycinDrug
vancomycin (125 mg qid)
| Study group | Role | What they receive |
|---|---|---|
| ridinilazole | Experimental | ridinilazole 200mg bid Receives: Drug: Ridinilazole |
| vancomycin | Active comparator | vancomycin 125 mg qid Receives: Drug: Vancomycin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Sustained Clinical Response (SCR) Defined as Clinical Response and no Recurrence of CDI Through 30 Days Post End of Treatment (EOT).
This primary outcome measures the number of participants with Sustained Clinical Response (SCR). SCR is defined as Clinical Response and no recurrence of CDI through 30 days post End of Treatment (EOT). At D40, D70 and D100 the Investigator or medically qualified designee will determine if the patient has a sustained clinical response or experienced RECURRENCE since the previous assessment. The Investigator will assess cure/failure and recurrence based on available information which includes, but is not limited to, improvement from baseline in the number of UBMs, signs \& symptoms of CDI, and the requirement for CDI medication. The Investigator should assess cure/failure in a way that best reflects the Investigator's standard clinical practice.
Measured: Day 40
Secondary outcomes (7)
Clinical Response
defined as
- less than 3 unformed bowel movements (UBMs) for consecutive days and maintained through EOT without further CDI treatment at EOT + 2 days, or
- the investigator's assessment that the subject no longer needs specific CDI antimicrobial treatment after completion of the course of study medication.
Measured: Day 12
Clinical Cure
defined as the resolution of diarrhea (<3 UBMs in the 1-day period immediately prior to EOT, that is maintained for 2 days after EOT).
Measured: Day 12
Sustained Clinical Response Over 60 Days
defined as Clinical Response and no recurrence of CDI through 60 days post EOT
Measured: Day 70
Sustained Clinical Response Over 90 Days
defined as Clinical Response and no recurrence of CDI through 90 days post EOT
Measured: Day 100
Relative Abundance of the 3 Main Bile Acid Groups (Conjugated Primary, Primary and Secondary Bile Acids) From Baseline to EOT.
This secondary outcome measures the relative abundance of the 3 main Bile Acid Groups (Conjugated Primary, Primary and Secondary Bile Acids) from Baseline to EOT.
Measured: Day 10
Percentage of Change of α-diversity (Shannon Index) of the Microbiota in Stool Samples From Baseline to EOT.
This secondary outcome measures the percentage of change of α-diversity (Shannon Index) of the microbiota in stool samples from baseline to EOT. Shannon index is a weighted statistic measuring both species richness and evenness. The Shannon Index is calculated by taking the relative abundance of each species and sums the relative abundance times the natural log of the relative abundance for each species. The value is converted into a positive value by times minus one. A higher Shannon Index means higher diversity
Measured: Day 10
Measure of β-diversity of the Gut Microbiota Between Baseline and EOT Stool Samples (Bray-Curtis Index/Dissimilarity).
This secondary outcome measures the β-diversity of the gut microbiota in stool samples from baseline to EOT. Bray-Curtis index/dissimilarity measures how different two samples are in the microbiome composition. The Bray-Curtis dissimilarity is graded between 0 and 1, where 0 means the two samples have the same composition (that is they share all the species and every species has the same abundance), and 1 means the two samples do not share any species.
Measured: Day 10
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2018
- Study start28 Jan 2019
- Primary completion17 Nov 2021
- Study completion17 Nov 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Clostridioides Difficile InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 759 participants (actual)
Sponsor and investigators
- Lead sponsor
- Summit Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Lori Styles, MD, Study director, Summit Therapeutics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03595553
- Sponsor's protocol ID
- SMT19969/C004
- Other IDs
- HHS0100201700014C
- Acronym
- Ri-CoDIFy 1
- Status last verified
- Oct 2026
- First submitted
- 11 Jun 2018
- Last updated
- 9 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Okhuysen PC, Ramesh MS, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira CM, Van Steenkiste C, Stychneuskaya A, Garey KW, Garcia-Diaz J, Li J, Duperchy E, Chang BY, Sukbuntherng J, Montoya JG, Styles L, Clow F, James D, Dubberke ER, Wilcox M. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 Jun 14;78(6):1462-1472. doi: 10.1093/cid/ciad792.
PubMed 38305378Carlson TJ, Endres BT, Basseres E, Gonzales-Luna AJ, Garey KW. Ridinilazole for the treatment of Clostridioides difficile infection. Expert Opin Investig Drugs. 2019 Apr;28(4):303-310. doi: 10.1080/13543784.2019.1582640. Epub 2019 Feb 26.
PubMed 30767587